These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 36980649)

  • 21. The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer.
    Giuliani J; Bonetti A
    J Oncol Pharm Pract; 2020 Sep; 26(6):1486-1491. PubMed ID: 32576084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
    Xi J; Ma CX
    Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
    Gul A; Leyland-Jones B; Dey N; De P
    Am J Cancer Res; 2018; 8(12):2359-2376. PubMed ID: 30662797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer.
    Barroso-Sousa R; Shapiro GI; Tolaney SM
    Breast Care (Basel); 2016 Jun; 11(3):167-73. PubMed ID: 27493615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A narrative review about CDK4/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer.
    Zhao S; Zhang H; Yang N; Yang J
    Transl Cancer Res; 2023 Jun; 12(6):1617-1634. PubMed ID: 37434680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
    Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
    Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting.
    Abdel-Razeq H; Sharaf B
    Drug Des Devel Ther; 2022; 16():727-735. PubMed ID: 35321498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection.
    Parati MC; Pedersini R; Perego G; Reduzzi R; Savio T; Cabiddu M; Borgonovo K; Ghilardi M; Luciani A; Petrelli F
    Breast Cancer (Dove Med Press); 2022; 14():101-111. PubMed ID: 35440873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis.
    Mastrantoni L; Orlandi A; Palazzo A; Garufi G; Fabi A; Daniele G; Giannarelli D; Tortora G; Bria E
    EClinicalMedicine; 2023 Feb; 56():101824. PubMed ID: 36713467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences.
    Johnston S; Emde A; Barrios C; Srock S; Neven P; Martin M; Cameron D; Janni W; Gnant M
    JNCI Cancer Spectr; 2023 Jul; 7(4):. PubMed ID: 37369022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CDK 4/6 inhibitors for adjuvant therapy in early breast cancer-Do we have a clear winner?
    Akhade A; Van Wambeke S; Gyawali B
    Ecancermedicalscience; 2022; 16():ed124. PubMed ID: 36200010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
    Hecht KA; Selby C
    Ann Pharmacother; 2019 Feb; 53(2):195-203. PubMed ID: 30079740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer.
    Echavarria I; Jerez Y; Martin M; López-Tarruella S
    Breast Care (Basel); 2017 Oct; 12(5):296-302. PubMed ID: 29234248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer.
    George MA; Qureshi S; Omene C; Toppmeyer DL; Ganesan S
    Front Oncol; 2021; 11():693104. PubMed ID: 34327137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.
    Martin M; Garcia-Saenz JA; Manso L; Llombart A; Cassinello A; Atienza M; Ringeisen F; Ciruelos E
    Future Oncol; 2020 Nov; 16(33):2763-2778. PubMed ID: 32781837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CDK4/6 inhibition in early and metastatic breast cancer: A review.
    de Groot AF; Kuijpers CJ; Kroep JR
    Cancer Treat Rev; 2017 Nov; 60():130-138. PubMed ID: 28961554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives.
    Roberto M; Astone A; Botticelli A; Carbognin L; Cassano A; D'Auria G; Fabbri A; Fabi A; Gamucci T; Krasniqi E; Minelli M; Orlandi A; Pantano F; Paris I; Pizzuti L; Portarena I; Salesi N; Scagnoli S; Scavina P; Tonini G; Vici P; Marchetti P
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33477469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
    Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of CDK4/6 Inhibitors in Breast Cancer.
    Murphy CG
    Curr Treat Options Oncol; 2019 May; 20(6):52. PubMed ID: 31101994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.